| Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance D Ge, J Fellay, AJ Thompson, JS Simon, KV Shianna, TJ Urban, ... Nature 461 (7262), 399-401, 2009 | 4551 | 2009 |
| Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection RK Sterling, E Lissen, N Clumeck, R Sola, MC Correa, J Montaner, ... Hepatology 43 (6), 1317-1325, 2006 | 4485 | 2006 |
| Boceprevir for untreated chronic HCV genotype 1 infection F Poordad, J McCone Jr, BR Bacon, S Bruno, MP Manns, MS Sulkowski, ... New England Journal of Medicine 364 (13), 1195-1206, 2011 | 3391 | 2011 |
| Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection JG McHutchison, EJ Lawitz, ML Shiffman, AJ Muir, GW Galler, J McCone, ... New England Journal of Medicine 361 (6), 580-593, 2009 | 1801 | 2009 |
| Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection N Afdhal, KR Reddy, DR Nelson, E Lawitz, SC Gordon, E Schiff, ... New England Journal of Medicine 370 (16), 1483-1493, 2014 | 1718 | 2014 |
| Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection MS Sulkowski, DF Gardiner, M Rodriguez-Torres, KR Reddy, ... New England Journal of Medicine 370 (3), 211-221, 2014 | 1593 | 2014 |
| Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options IM Jacobson, SC Gordon, KV Kowdley, EM Yoshida, M Rodriguez-Torres, ... New England journal of medicine 368 (20), 1867-1877, 2013 | 1436 | 2013 |
| Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection JG McHutchison, GT Everson, SC Gordon, IM Jacobson, M Sulkowski, ... New England Journal of Medicine 360 (18), 1827-1838, 2009 | 1430 | 2009 |
| Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection MS Sulkowski, DL Thomas, RE Chaisson, RD Moore JAMA: The Journal of the American Medical Association 283 (1), 74, 2000 | 1312 | 2000 |
| Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and … E Lawitz, MS Sulkowski, R Ghalib, M Rodriguez-Torres, ZM Younossi, ... The Lancet 384 (9956), 1756-1765, 2014 | 1070 | 2014 |
| Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection GR Foster, N Afdhal, SK Roberts, N Bräu, EJ Gane, S Pianko, E Lawitz, ... New England Journal of Medicine 373 (27), 2608-2617, 2015 | 1064 | 2015 |
| Response-guided telaprevir combination treatment for hepatitis C virus infection KE Sherman, SL Flamm, NH Afdhal, DR Nelson, MS Sulkowski, ... New England Journal of Medicine 365 (11), 1014-1024, 2011 | 1052 | 2011 |
| Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States SH Mehta, FL Brancati, MS Sulkowski, SA Strathdee, M Szklo, DL Thomas Annals of internal medicine 133 (8), 592-599, 2000 | 984 | 2000 |
| Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus AJ Thompson, AJ Muir, MS Sulkowski, D Ge, J Fellay, KV Shianna, ... Gastroenterology 139 (1), 120-129. e18, 2010 | 970 | 2010 |
| Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease M Charlton, GT Everson, SL Flamm, P Kumar, C Landis, RS Brown Jr, ... Gastroenterology 149 (3), 649-659, 2015 | 957 | 2015 |
| Hepatitis C guidance: AASLD‐IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus AASLD/IDSA HCV Guidance Panel, RT Chung, GL Davis, DM Jensen, ... Hepatology 62 (3), 932-954, 2015 | 838 | 2015 |
| Retreatment of HCV with ABT-450/r–ombitasvir and dasabuvir with ribavirin S Zeuzem, IM Jacobson, T Baykal, RT Marinho, F Poordad, M Bourlière, ... New England Journal of Medicine 370 (17), 1604-1614, 2014 | 780 | 2014 |
| Hepatotoxicity associated with nevirapine or efavirenz‐containing antiretroviral therapy: role of hepatitis C and B infections MS Sulkowski, DL Thomas, SH Mehta, RE Chaisson, RD Moore Hepatology 35 (1), 182-189, 2002 | 761 | 2002 |
| Oral direct-acting agent therapy for hepatitis C virus infection: a systematic review O Falade-Nwulia, C Suarez-Cuervo, DR Nelson, MW Fried, JB Segal, ... Annals of internal medicine 166 (9), 637-648, 2017 | 752 | 2017 |
| Hepatitis C and progression of HIV disease MS Sulkowski, RD Moore, SH Mehta, RE Chaisson, DL Thomas JAMA: the journal of the American Medical Association 288 (2), 199, 2002 | 634 | 2002 |
